Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$2.62 USD
-0.13 (-4.73%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $2.62 0.00 (0.00%) 6:34 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADPT 2.62 -0.13(-4.73%)
Will ADPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
Exploring Analyst Estimates for Adaptive Biotechnologies (ADPT) Q4 Earnings, Beyond Revenue and EPS
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?
Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
Other News for ADPT
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
BTIG Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)